Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Machine Learning to Predict Early Relapse in Multiple Myeloma

Uses machine learning to predict treatment response and early relapse in adults with myeloma.

Plain-language title generated from the registry record
Registry title: A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence

Key facts

Where
Bologna, Cagliari, Meldola, and Naples, ItalySee the 4 sites

Where in Italy

  • IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, ItalyTaking people
  • ARNAS "G. Brotzu" di CagliariCagliari, ItalyNot yet recruiting
  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCSMeldola, ItalyNot yet recruiting
  • Azienda Ospedaliera Universitaria Federico IINaples, ItalyNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Trial code
NCT06767254
Record updated
9 January 2025
Original description
This is a non-interventional, national, multicenter prospective non-profit observational study aiming at improving the accuracy of risk prediction in multiple myeloma (MM) by applying machine-learning tools for data processing to develop model(s) predicting response to therapy and the probability of early relapse for MM patients.Read full original descriptionShow less

A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence

This is a non-interventional, national, multicenter prospective non-profit observational study aiming at improving the accuracy of risk prediction in multiple myeloma (MM) by applying machine-learning tools for data processing to develop model(s) predicting response to therapy and the probability of early relapse for MM patients.

Inclusion: Age ≥ 18 years; Signed Informed Consent form for study participation and personal data processing; Diagnosis of active multiple myeloma.

Exclusion: None.

ClinicalTrials.gov NCT06767254